Payment overview · 2025
General Payments
$589.66
35 reported records · 6 companies
Healthcare provider profile · identity verified
Mark E Reed, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PIKEVILLE, KY · NPI 1992768261
Verified facts
What the public records show
CMS Open Payments records show Mark E Reed, M.D. received $589.66 in general payments during 2025 across 35 reported records.
Novo Nordisk Inc accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $213.97 | 36.3% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.96 | 25.1% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.66 | 16.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.98 | 11.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.47 | 8.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.62 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $589.66 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $192.23 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $147.96 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $144.28 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $109.32 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $97.66 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.98 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.97 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.64 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.12 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 340 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
175 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
340 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1209 | 226 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1030 | 180 |
| Pantoprazole Sodium | Pantoprazole Sodium | 840 | 165 |
| Omeprazole | Omeprazole | 804 | 148 |
| Losartan Potassium | Losartan Potassium | 781 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 731 | 149 |
| Gabapentin | Gabapentin | 647 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 590 | 112 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 587 | 101 |
| Lisinopril | Lisinopril | 574 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 476 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 474 | 101 |
| Azithromycin | Azithromycin | 471 | 340 |
| Metformin Hcl | Metformin Hcl | 451 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 448 | 82 |
| Lorazepam | Lorazepam | 419 | 63 |
| Potassium Chloride | Potassium Chloride | 398 | 86 |
| Alprazolam | Alprazolam | 390 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 369 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 365 | 71 |
| Furosemide | Furosemide | 364 | 80 |
| Clonazepam | Clonazepam | 352 | 40 |
| Montelukast Sodium | Montelukast Sodium | 348 | 71 |
| Ibuprofen | Ibuprofen | 341 | 94 |
| Zolpidem Tartrate | Zolpidem Tartrate | 341 | 50 |
| Ozempic | Semaglutide | 340 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 331 | 74 |
| Famotidine | Famotidine | 328 | 66 |
| Simvastatin | Simvastatin | 326 | 68 |
| Tramadol Hcl | Tramadol Hcl | 322 | 59 |
| Meloxicam | Meloxicam | 302 | 64 |
| Celecoxib | Celecoxib | 296 | 52 |
| Methylprednisolone | Methylprednisolone | 259 | 208 |
| Metformin Hcl Er | Metformin Hcl | 246 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 235 | 44 |
| Sertraline Hcl | Sertraline Hcl | 230 | 38 |
| Trazodone Hcl | Trazodone Hcl | 212 | 43 |
| Glimepiride | Glimepiride | 211 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 211 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 210 | 50 |
| Bupropion Xl | Bupropion Hcl | 201 | 31 |
| Eliquis | Apixaban | 197 | 39 |
| Carvedilol | Carvedilol | 196 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 196 | 38 |
| Donepezil Hcl | Donepezil Hcl | 194 | 36 |
| Synthroid | Levothyroxine Sodium | 175 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 163 | 33 |
| Cefdinir | Cefdinir | 160 | 114 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 157 | 24 |
| Diazepam | Diazepam | 156 | 21 |
| Temazepam | Temazepam | 153 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 152 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 150 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 146 | 29 |
| Meclizine Hcl | Meclizine Hcl | 141 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 140 | 40 |
| Pregabalin | Pregabalin | 133 | 23 |
| Prednisone | Prednisone | 128 | 76 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 126 | 14 |
| Glipizide Er | Glipizide | 125 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 124 | 105 |
| Amoxicillin | Amoxicillin | 122 | 97 |
| Glipizide | Glipizide | 116 | 22 |
| Atenolol | Atenolol | 113 | 23 |
| Spironolactone | Spironolactone | 106 | 18 |
| Allopurinol | Allopurinol | 105 | 23 |
| Ezetimibe | Ezetimibe | 105 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 103 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 23 |
| Jardiance | Empagliflozin | 103 | 20 |
| Nystatin | Nystatin | 103 | 28 |
| Buspirone Hcl | Buspirone Hcl | 98 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 17 |
| Trulicity | Dulaglutide | 96 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 18 |
| Valsartan | Valsartan | 93 | 18 |
| Naproxen | Naproxen | 91 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 87 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 32 |
| Fluconazole | Fluconazole | 80 | 54 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 76 | 55 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 13 |
| Xarelto | Rivaroxaban | 76 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 71 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 70 | suppressed |
| Finasteride | Finasteride | 70 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 70 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 67 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 66 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 13 |
| Lansoprazole | Lansoprazole | 64 | 13 |
| Primidone | Primidone | 64 | 14 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Sucralfate | Sucralfate | 60 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 18 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 55 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 13 |
| Linzess | Linaclotide | 53 | 14 |
| Baclofen | Baclofen | 51 | 11 |
| Cephalexin | Cephalexin | 50 | 34 |
| Ibu | Ibuprofen | 49 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Estradiol | Estradiol | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Bumetanide | Bumetanide | 45 | 12 |
| Hydrocortisone | Hydrocortisone | 45 | 17 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Sotalol | Sotalol Hcl | 43 | suppressed |
| Dutasteride | Dutasteride | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 27 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 39 | 11 |
| Topiramate | Topiramate | 39 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 38 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 17 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $589.66 · 35 records | Novo Nordisk Inc | CREON, ELIQUIS, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error